LEADER 02379nam  2200553 a 450 
001 9910877816203321
005 20200520144314.0
010   $a3-527-64467-9
010   $a1-283-14044-6
010   $a9786613140449
010   $a3-527-63007-4
010   $a3-527-63008-2
035   $a(CKB)2670000000019017
035   $a(EBL)530455
035   $a(SSID)ssj0000430139
035   $a(PQKBManifestationID)11965379
035   $a(PQKBTitleCode)TC0000430139
035   $a(PQKBWorkID)10453602
035   $a(PQKB)10919303
035   $a(MiAaPQ)EBC530455
035   $a(OCoLC)644165307
035   $a(EXLCZ)992670000000019017
100   $a20100612d2010      uy         0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 00$aTuberous sclerosis complex $egenes, clinical features and therapeutics /$fedited by David J. Kwiatkowski, Vicky Holets Whittemore, and Elizabeth A. Thiele
210   $aWeinheim $cWiley-Blackwell$d2010
215   $a1 online resource (433 p.)
300   $aDescription based upon print version of record.
311   $a3-527-32201-9 
320   $aIncludes bibliographical references and index.
327   $apt. 1. Basics -- pt. 2. Genetics -- pt. 3. Basic sciences -- pt. 4. Brain involvement -- pt. 5. Other organ systems -- pt. 6. Family impact.
330   $aThe only comprehensive overview of the molecular basis and clinical features of the genetic disorder tuberous sclerosis, which affects approximately 50,000 people in the US alone. Special focus is placed on novel insights into the signal transduction pathways affected by the disease as well as genotype phenotype correlations, while existing and potential therapies are also discussed in depth. The editors are leading experts in research and treatment of the disease as well as the Vice President of the Tuberous Sclerosis Alliance, the only voluntary health organization for TSC in the US.
606   $aTuberous sclerosis
615  0$aTuberous sclerosis.
676   $a616.8
701   $aKwiatkowski$b David J$01751318
701   $aWhittemore$b Vicky Holets$01751319
701   $aThiele$b Elizabeth A$01751320
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910877816203321
996   $aTuberous sclerosis complex$94186221
997   $aUNINA